Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy

Critical Reviews in Oncology/Hematology

Volumn 78, Issue 3, 2011, Pages 252-259

  Nakai, Yousuke ^a   Isayama, Hiroyuki ^a   Sasaki, Takashi ^a   Sasahira, Naoki ^a   Tsujino, Takeshi ^a   Kogure, Hirofumi ^a   Yagioka, Hiroshi ^a   Yashima, Yoko ^a   Togawa, Osama ^a   Arizumi, Toshihiko ^a   Matsubara, Saburo ^a   Hirano, Kenji ^a   Tada, Minoru ^a   Omata, Masao ^b   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Age; Chemotherapy; Comorbidity; Gemcitabine; Pancreatic cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ADULT; ADVANCED CANCER; AGE; AGED; ANEMIA; ANOREXIA; CANCER SURVIVAL; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PROGNOSIS; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; DEOXYCYTIDINE; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79955664740     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.05.007     Document Type: Review

References (25)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
2. National Cancer Institute. SEER Cancer Statistics Review; 1975-2006. Available at http://seer.cancer.gov/csr/1975_2006/.
3. Yip D., Karapetis C., Strickland A., Steer C.B., Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006, 3:CD002093.
4. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341(27):2061-2067.
5. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
6. Locher C., Fabre-Guillevin E., Brunetti F., et al. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol 2008, 68(2):178-182.
7. Marechal R., Demols A., Gay F., et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008, 36(3):e16-e21.
8. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
9. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47(11):1245-1251.
10. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16(4):1582-1587.
11. Nakai Y., Isayama H., Sasaki T., et al. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology 2009, 77(5):300-303.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
13. Hardacre J.M., Simo K., McGee M.F., Stellato T.A., Schulak J.A. Pancreatic resection in octogenarians. J Surg Res 2009.
14. Davila J.A., Chiao E.Y., Hasche J.C., Petersen N.J., McGlynn K.A., Shaib Y.H. Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas 2009, 38(1):e18-e25.
15. Scurtu R., Bachellier P., Oussoultzoglou E., Rosso E., Maroni R., Jaeck D. Outcome after pancreaticoduodenectomy for cancer in elderly patients. J Gastrointest Surg 2006, 10(6):813-822.
16. Pallis A.G., Polyzos A., Boukovinas I., et al. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. J Thorac Oncol 2008, 3(5):505-510.
17. Asmis T.R., Ding K., Seymour L., et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008, 26(1):54-59.
18. Pasetto L.M., Stefano T., Rossi E., Paris M.K., Monfardini S. Treatment of stage IV colorectal carcinoma in elderly patients. Crit Rev Oncol Hematol 2005, 54(2):145-155.
19. Sastre J., Aranda E., Massuti B., et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol 2009, 70(2):134-144.
20. Jackson N.A., Barrueco J., Soufi-Mahjoubi R., et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 2009, 115(12):2617-2629.
21. Hanada K., Hino F., Amano H., Fukuda T., Kuroda Y. Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging 2006, 23(5):403-410.
22. Aparicio T., Desrame J., Lecomte T., et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003, 89(8):1439-1444.
23. Aparicio T., Navazesh A., Boutron I., et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol 2009, 71(3):249-257.
24. Firat S., Bousamra M., Gore E., Byhardt R.W. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 52(4):1047-1057.
25. Firat S., Byhardt R.W., Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002, 54(2):357-364.